Molecular Therapeutics Theme 2 Accomplishments

Theme 2: Identify cellular/molecular determinants and clinically relevant biomarkers of treatment response on which to base therapy

Scientific Accomplishments 

Drs. Bepler, Gadgeel, A Schwartz, and Cote, working with Dr. Bollig-Fischer, identified “driver” mutations in non-small cell lung cancer (NSCLC) in African American and European American patients using the Sequenom MassArray system and a multiplexed panel for 214 oncogenic mutations in 26 genes previously identified in NSCLC. African Americans with NSCLC exhibited multiple genetic mutations more frequently than European Americans with a different mutation profile. These results provided impetus for CAP/CLIA certification of the Genomics Core in 2013 for use of custom panels for lung cancer oncogenes and amplifications/deletions.

  • Lead researchers - Drs. Bepler, Gadgeel, and Bollig-Fischer
  • Collaborative researchers - Drs. Schwartz and Cote

Dr. Ratnam, working with Drs. Gadgeel, Shields, Matherly, and Bepler, demonstrated the role of glucocorticoid receptor (GR) status as a determinant of the variability in the sensitivity of non-small cell lung cancer (NSCLC) cells to pemetrexed (PEM), a S-phase-targeted drug in front-line or maintenance therapy  of advanced NSCLC, generally administered with dexamethasone (Dex). Their results predict that in non-squamous NSCLC, S-phase suppression by Dex, combined with a reduction in PEM transport, attenuates responsiveness to PEM and that GR status is an important determinant of tumor variability of this response.  Based on these in vitro results, an investigator-initiated clinical trial (Shields, Lead PI; Ratnam, Gadgeel, Heilbrun, collaborators) is enrolling NSCLC patients who will be screened by RT-PCR for high levels of GRα, then imaged with FLT-PET to test the hypothesis that Dex will decrease S-phase progression, as reflected in decreased activity of thymidine kinase-1.

  • Lead researchers - Drs. Ratnam. Gadgeel, Shields, Matherly and Bepler.
  • Collaborative researcher - Dr. Heilbrun

The Latest From Karmanos Cancer Institute

News

Beating back cancer

“To hear that was a godsend.” It was a familiar face that delivered the news to Lori. It was Nov. 29, and Lori was sitting in the McLaren Oakland ...

Read More

Johanna’s Legacy: Tribute gift supports better treatments for ovarian cancer

Give women the facts and they will take care of their health. That’s the premise behind the philanthropic drive of Sheryl Silver, a leading nation...

Read More

Time to Do a Skin Check

“Right now is a good time to take inventory of your skin.” There was plenty of sun in Michigan this summer. Spending more time outdoors and enjoyi...

Read More
News

ACS CAN Michigan Candid Connection, August 2021 — April Brown

Listen Now

Dr. Al Hallak on alcohol and cancer with WJR

Listen Now

ACS CAN MI CANdid Connection, July 2021 — Anthony Shields, M.D.

Listen Now